Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04596670
EARLY_PHASE1

68Ga-ICAM-1pep PET/CT in Cancer Patients

Sponsor: Peking University Cancer Hospital & Institute

View on ClinicalTrials.gov

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients receiving radiotherapy. A single dose of 2.96 MBq/kg body weight of 68Ga-ICAM-1pep will be injected intravenously. The visual and semiquantitative methods will be used to assess the PET/CT images.

Official title: 68Ga-ICAM-1pep PET/CT Imaging of Tumor Responses to Radiotherapy in Cancer Patients

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-09-20

Completion Date

2025-12-31

Last Updated

2024-08-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

68Ga-ICAM-1pep

68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China